Bridgeway Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Bridgeway Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,003	Closed	-$55.3K	–	1280
2024 Q1	$55.3K	Hold	3,003	–	–	﹤0.01%	1260
2023 Q4	$47.7K	Hold	3,003	–	–	﹤0.01%	1317
2023 Q3	$56.6K	Hold	3,003	–	–	﹤0.01%	1290
2023 Q2	$67.9K	Buy	+3,003	New	+$70.6K	﹤0.01%	1306
2022 Q4	–	Sell	-7,000	Closed	-$88K	–	1384
2022 Q3	$88K	Sell	7,000 -5,000	-42%	-$69K	﹤0.01%	1296
2022 Q2	$117K	Sell	12,000 -500	-4%	-$6.18K	﹤0.01%	1198
2022 Q1	$208K	Sell	12,500 -4,860	-28%	-$82.4K	﹤0.01%	1165
2021 Q4	$441K	Buy	17,360 +11,416	+192%	+$355K	0.01%	1017
2021 Q3	$266K	Hold	5,944	–	–	0.01%	1174
2021 Q2	$240K	Sell	5,944 -2,250	-27%	-$95.2K	﹤0.01%	1239
2021 Q1	$436K	Sell	8,194 -5,999	-42%	-$296K	0.01%	1128
2020 Q4	$568K	Buy	14,193 +5,343	+60%	+$266K	0.01%	901
2020 Q3	$504K	Hold	8,850	–	–	0.01%	881
2020 Q2	$653K	Buy	8,850 +2,500	+39%	+$162K	0.01%	780
2020 Q1	$315K	Buy	6,350 +1,186	+23%	+$71.1K	0.01%	917
2019 Q4	$397K	Buy	5,164 +445	+9%	+$20.4K	0.01%	1062
2019 Q3	$188K	Hold	4,719	–	–	﹤0.01%	1192
2019 Q2	$159K	Hold	4,719	–	–	﹤0.01%	1211
2019 Q1	$250K	Buy	4,719 +1,500	+47%	+$82.2K	﹤0.01%	1188
2018 Q4	$151K	Sell	3,219 -5,731	-64%	-$409K	﹤0.01%	1255
2018 Q3	$788K	Buy	8,950 +4,250	+90%	+$375K	0.01%	992
2018 Q2	$489K	Hold	4,700	–	–	0.01%	1136
2018 Q1	$376K	Hold	4,700	–	–	﹤0.01%	1156
2017 Q4	$639K	Buy	4,700 +1,250	+36%	+$190K	0.01%	1012
2017 Q3	$559K	Buy	3,450 +1,250	+57%	+$178K	0.01%	1060
2017 Q2	$330K	Buy	2,200 +200	+10%	+$27.6K	﹤0.01%	1190
2017 Q1	$312K	Sell	2,000 -2,000	-50%	-$351K	﹤0.01%	1202
2016 Q4	$832K	Hold	4,000	–	–	0.01%	889
2016 Q3	$916K	Hold	4,000	–	–	0.01%	835
2016 Q2	$825K	Buy	+4,000	New	+$968K	0.01%	853

Other funds holding CDTX

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Bridgeway Capital Management's CDTX Position: Q2 2024 in Review

Bridgeway Capital Management sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 3,003 shares — an estimated $55.3K sold.

Bridgeway Capital Management first reported a position in CDTX in Q2 2016 and held it in 30 quarters. The position peaked at $916K in Q3 2016. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

Bridgeway Capital Management reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
Bridgeway Capital Management sold 3,003 Cidara Therapeutics shares in Q2 2024, an estimated $55.3K.
Bridgeway Capital Management first reported a position in Cidara Therapeutics in Q2 2016 and held it in 30 quarters.
Bridgeway Capital Management's Cidara Therapeutics position peaked at $916K in Q3 2016.
26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.